Magazine Article | May 2, 2022

A New Golden Age Of Psychedelic Therapy? Proceed With Caution

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

It was eye-opening for me, as I expect it will be for many readers of Life Science Leader, to learn that the Multidisciplinary Association for Psychedelic Studies (MAPS) aims to dose 1 million post-traumatic stress disorder (PTSD) patients with MDMA by 2031. MDMA, which MAPS founder and executive director Rick Doblin has called the “gentlest” of the psychedelic compounds currently being investigated for therapeutic use, is expected to receive the FDA’s blessing during the first half of 2024, if not sooner.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: